Haemodynamic and clinical effects of ularitide in decompensated heart failure
Autori
Mitrovic, VeselinSeferovic, Petar M.
Simeunovic, Dejan
Ristic, Arsen D.
Miric, Milutin
Moiseyev, Valentin S.
Kobalava, Zhanna
Nitsche, Klaus
Forssmann, Wolf-Georg
Luess, Hartmut
Meyer, Markus
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Aims Ularitide is a synthetic form of urodilatin, a natriuretic peptide produced in the kidney with vasodilating, natriuretic, and diuretic effects, that offers promise for the management of decompensated heart failure (DHF). We assessed the efficacy and safety of ularitide in treating patients with DHF. Methods and results In this Phase II randomized, double-blind, placebo-controlled trial, 221 DHF patients received either placebo (n=53) or ularitide at 7.5 ng/kg/min (n=60), 15 ng/kg/min (n=53), or 30 ng/kg/min (n=55) as a 24-h continuous infusion. At 6 h, ularitide demonstrated a significant decrease in pulmonary capillary wedge pressure (P=0.052, P=0.000004, P=0.000002, respectively) and improved dyspnoea score in the 7.5, 15, and 30 ng/kg/min ularitide group (P=0.0026, P=0.0026, P=0.0013, respectively). Ularitide reduced systemic vascular resistance and increased cardiac index for the 15 and 30 ng/kg/min groups (P=0.017, P=0.00002, respectively). Systolic blood pressure (BP) decrea...sed dose dependency. Heart rate and serum creatinine were unchanged through day 3. Most frequently reported drug-related adverse events through day 3 in all ularitide groups were dose-dependent BP decrease and hypotension. Conclusion Ularitide lowered cardiac filling pressures and improved dyspnoea without apparent early deleterious effects on renal function in DHF patients. These results suggest that ularitide may play a role in the management of DHF.
Ključne reči:
natriuretic peptide / urodilatin / ularitide / decompensated heart failure / congestive heart failure / randomized clinical trialIzvor:
European Heart Journal, 2006, 27, 23, 2823-2832
DOI: 10.1093/eurheartj/ehl337
ISSN: 0195-668X
PubMed: 17074775
WoS: 000242472100015
Scopus: 2-s2.0-33845342902
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Mitrovic, Veselin AU - Seferovic, Petar M. AU - Simeunovic, Dejan AU - Ristic, Arsen D. AU - Miric, Milutin AU - Moiseyev, Valentin S. AU - Kobalava, Zhanna AU - Nitsche, Klaus AU - Forssmann, Wolf-Georg AU - Luess, Hartmut AU - Meyer, Markus PY - 2006 UR - https://vinar.vin.bg.ac.rs/handle/123456789/3125 AB - Aims Ularitide is a synthetic form of urodilatin, a natriuretic peptide produced in the kidney with vasodilating, natriuretic, and diuretic effects, that offers promise for the management of decompensated heart failure (DHF). We assessed the efficacy and safety of ularitide in treating patients with DHF. Methods and results In this Phase II randomized, double-blind, placebo-controlled trial, 221 DHF patients received either placebo (n=53) or ularitide at 7.5 ng/kg/min (n=60), 15 ng/kg/min (n=53), or 30 ng/kg/min (n=55) as a 24-h continuous infusion. At 6 h, ularitide demonstrated a significant decrease in pulmonary capillary wedge pressure (P=0.052, P=0.000004, P=0.000002, respectively) and improved dyspnoea score in the 7.5, 15, and 30 ng/kg/min ularitide group (P=0.0026, P=0.0026, P=0.0013, respectively). Ularitide reduced systemic vascular resistance and increased cardiac index for the 15 and 30 ng/kg/min groups (P=0.017, P=0.00002, respectively). Systolic blood pressure (BP) decreased dose dependency. Heart rate and serum creatinine were unchanged through day 3. Most frequently reported drug-related adverse events through day 3 in all ularitide groups were dose-dependent BP decrease and hypotension. Conclusion Ularitide lowered cardiac filling pressures and improved dyspnoea without apparent early deleterious effects on renal function in DHF patients. These results suggest that ularitide may play a role in the management of DHF. T2 - European Heart Journal T1 - Haemodynamic and clinical effects of ularitide in decompensated heart failure VL - 27 IS - 23 SP - 2823 EP - 2832 DO - 10.1093/eurheartj/ehl337 ER -
@article{ author = "Mitrovic, Veselin and Seferovic, Petar M. and Simeunovic, Dejan and Ristic, Arsen D. and Miric, Milutin and Moiseyev, Valentin S. and Kobalava, Zhanna and Nitsche, Klaus and Forssmann, Wolf-Georg and Luess, Hartmut and Meyer, Markus", year = "2006", abstract = "Aims Ularitide is a synthetic form of urodilatin, a natriuretic peptide produced in the kidney with vasodilating, natriuretic, and diuretic effects, that offers promise for the management of decompensated heart failure (DHF). We assessed the efficacy and safety of ularitide in treating patients with DHF. Methods and results In this Phase II randomized, double-blind, placebo-controlled trial, 221 DHF patients received either placebo (n=53) or ularitide at 7.5 ng/kg/min (n=60), 15 ng/kg/min (n=53), or 30 ng/kg/min (n=55) as a 24-h continuous infusion. At 6 h, ularitide demonstrated a significant decrease in pulmonary capillary wedge pressure (P=0.052, P=0.000004, P=0.000002, respectively) and improved dyspnoea score in the 7.5, 15, and 30 ng/kg/min ularitide group (P=0.0026, P=0.0026, P=0.0013, respectively). Ularitide reduced systemic vascular resistance and increased cardiac index for the 15 and 30 ng/kg/min groups (P=0.017, P=0.00002, respectively). Systolic blood pressure (BP) decreased dose dependency. Heart rate and serum creatinine were unchanged through day 3. Most frequently reported drug-related adverse events through day 3 in all ularitide groups were dose-dependent BP decrease and hypotension. Conclusion Ularitide lowered cardiac filling pressures and improved dyspnoea without apparent early deleterious effects on renal function in DHF patients. These results suggest that ularitide may play a role in the management of DHF.", journal = "European Heart Journal", title = "Haemodynamic and clinical effects of ularitide in decompensated heart failure", volume = "27", number = "23", pages = "2823-2832", doi = "10.1093/eurheartj/ehl337" }
Mitrovic, V., Seferovic, P. M., Simeunovic, D., Ristic, A. D., Miric, M., Moiseyev, V. S., Kobalava, Z., Nitsche, K., Forssmann, W., Luess, H.,& Meyer, M.. (2006). Haemodynamic and clinical effects of ularitide in decompensated heart failure. in European Heart Journal, 27(23), 2823-2832. https://doi.org/10.1093/eurheartj/ehl337
Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann W, Luess H, Meyer M. Haemodynamic and clinical effects of ularitide in decompensated heart failure. in European Heart Journal. 2006;27(23):2823-2832. doi:10.1093/eurheartj/ehl337 .
Mitrovic, Veselin, Seferovic, Petar M., Simeunovic, Dejan, Ristic, Arsen D., Miric, Milutin, Moiseyev, Valentin S., Kobalava, Zhanna, Nitsche, Klaus, Forssmann, Wolf-Georg, Luess, Hartmut, Meyer, Markus, "Haemodynamic and clinical effects of ularitide in decompensated heart failure" in European Heart Journal, 27, no. 23 (2006):2823-2832, https://doi.org/10.1093/eurheartj/ehl337 . .